MMP-7-IN-2

CAS No. 2848717-49-5

MMP-7-IN-2( —— )

Catalog No. M37148 CAS No. 2848717-49-5

MMP-7-IN-2 acts as a selective and potent MMP7 inhibitor and can be used to study inflammatory responses and vascular-related diseases.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 385 Get Quote
5MG 591 Get Quote
10MG 1064 Get Quote
25MG 1527 Get Quote
50MG 2052 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    MMP-7-IN-2
  • Note
    Research use only, not for human use.
  • Brief Description
    MMP-7-IN-2 acts as a selective and potent MMP7 inhibitor and can be used to study inflammatory responses and vascular-related diseases.
  • Description
    MMP-7-IN-2 (comp 16) is a selective MMP7 inhibitor, with an IC50 of 16 nM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    MMP
  • Recptor
    MMP
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2848717-49-5
  • Formula Weight
    729.17
  • Molecular Formula
    C28H40ClF3N6O9S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (137.14 mM; Ultrasonic )
  • SMILES
    S(N[C@@H](CCC(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)C)=O)C(C)C)=O)CC(C)C)=O)=O)C(O)=O)(=O)(=O)C1=CC(C(F)(F)F)=C(Cl)C=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Hideaki Tabuse, et al. Discovery of Highly Potent and Selective Matrix Metalloproteinase-7 Inhibitors by Hybridizing the S1' Subsite Binder with Short Peptides. J Med Chem. 2022 Oct 13;65(19):13253-13263.?
molnova catalog
related products
  • MMP-7-IN-2

    MMP-7-IN-2 acts as a selective and potent MMP7 inhibitor and can be used to study inflammatory responses and vascular-related diseases.

  • Pectolinarigenin

    Pectolinarigenin possesses anti-inflammatory activity and that they may inhibit eicosanoid formation in inflammatory lesions.

  • Andecaliximab

    Andecaliximab is a recombinant IgG4 monoclonal antibody targeting matrix metalloproteinase 9 (MMP9). Andecaliximab showed antifibrotic effects in a mouse model of idiopathic pulmonary fibrosis.